Abstract Alcohol use disorders (AUD) cause significant morbidity and mortality worldwide, but pharmacological treatments for them are underused, despite evidence of efficacy. Acamprosate, naltrexone, nalmefene and disulfiram are all approved in one or more region for the treatment of AUD. Baclofen currently has a temporary indication in France. Safety considerations for using psychopharmacological treatments in this patient group include the impact of concurrent alcohol consumption at high levels; multiple physical comorbidities that may interfere with pharmacological effects, distribution and metabolism; and concomitant medication for the treatment of comorbid physical and psychiatric conditions. The five drugs, including an extended-release injectable suspension of naltrexone, have different safety profiles that need to be balanced with the treatment objective (initiation or continuation of abstinence, or reduction of drinking), individual patient preferences and comorbid conditions. Appropriate treatment will be based on the unique riskbenefit profile in each case.
Introduction
Alcohol use disorders (AUD) are common and disabling conditions, with 3.3 million deaths (5.9 % of global deaths) and 5.1 % of the global burden of disease and injury in 2012 attributable to them [1] . Alcohol dependence (International Statistical Classification of Diseases and Related Health Problems, 10th revision [ICD-10]) or severe alcohol use disorders (Diagnostic and Statistical Manual of Mental Disorders ) are frequently under-treated, with estimates of treatment in \25 % of affected individuals in the USA [2] and \10 % in Europe [3] . The mainstay of treatment is psychosocial [4] , but there is a good evidence base for the effectiveness of pharmacological treatment in medically assisted alcohol withdrawal [5] , in Electronic supplementary material The online version of this article (doi:10.1007/s40264-016-0416-y) contains supplementary material, which is available to authorized users. relapse prevention and in reduction of alcohol consumption [4, [6] [7] [8] .
Safety considerations for any medication include the pharmacokinetics of the drug; the range of adverse drug reactions [9] ; the patient population, including age, sex, ethnicity and interaction with underlying pathology, including co-morbid conditions; and interactions with other medications. In patients with alcohol dependence, the interaction of the treatment with alcohol consumption, the consequences of self-poisoning and the abuse liability also need to be considered.
The focus of this article is on safety considerations of medications with an indication for relapse prevention or alcohol reduction in patients with alcohol dependence; specifically acamprosate, naltrexone, disulfiram, nalmefene and baclofen. Whilst AUD are frequently comorbid with other conditions, especially in treatment-seeking populations, there is limited evidence for the impact of comorbidity or the associated polypharmacy on safety considerations. Many of the medications with an indication for AUD have been tried in other substance use and behavioural addictions but have had insufficient efficacy to gain an indication and so are not reviewed here.
Literature Review Methodology
We conducted a comprehensive review informed by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [10, 11] . All included and excluded studies in two recent systematic reviews of randomized controlled trials (RCTs) [4, 6, 7] were screened for potential eligibility. We reviewed papers published since 2010 to find studies that were not included in the UK National Institute for Health and Care Excellence (NICE) and Cochrane reviews. We searched PsycINFO, MEDLINE and Embase with the terms ('alcohol' OR 'drinking') AND ('safety' OR 'toxicity' OR 'adverse effects' OR 'adverse events' OR 'overdose' OR 'tolerability' OR 'side effects' OR 'misuse' OR 'harm' OR 'hazard' OR 'contraindications' OR 'poisoning' OR 'complication' OR 'pharmacovigilance' OR 'phase four/4 0 OR 'post marketing surveillance' OR 'pharmacoepidemiology') for each of the following drugs: acamprosate, naltrexone, disulfiram, nalmefene and baclofen. We included all papers with an abstract in English that met the inclusion criteria.
We also examined the bibliographic references of papers published after 2010 to ensure all relevant literature was included and contacted key authors in the field with reference lists to ensure no key publications on safety and tolerability had been excluded (see the Acknowledgments section). We also reviewed any links from the European Public Assessment Reports (EPARs) and Summaries of Product Characteristics (SPCs) to published references.
We only included studies where alcohol dependence was the primary condition (thereby excluding 'social drinkers' and hazardous, harmful or abusive drinking) and safety/tolerability information was reported. Attribution of causality of adverse events requires a systematic approach to reporting that is frequently lacking [12] . Given the complex interaction between subjective experience in patients with alcohol dependence and symptoms of alcohol withdrawal, it is especially difficult to distinguish between alcohol-related symptoms and drug-related side effects, and so single case studies were excluded. Our complete search strategy is shown in Fig. 1 .
Acamprosate
Acamprosate (calcium acetylhomotaurinate) is licensed for relapse prevention in the UK, Australasia, North America and much of Europe. It modulates the N-methyl-D-aspartate (NMDA) receptor and indirectly enhances c-aminobutyric acid (GABA) function, both of which are altered during alcohol withdrawal and the early stages of abstinence [13] . A significant decrease in frontal lobe glutamate has been shown on magnetic resonance spectroscopy (MRS) in patients receiving acamprosate in the early stages of abstinence compared with placebo [14] . This may account for the reduction in arousal, anxiety and insomnia (all negative reinforcers implicated in relapse back to heavy drinking) seen in patients receiving acamprosate in the early stages of abstinence [8] . Acamprosate has low oral bioavailability (approximately 11 %), is not protein bound and is not metabolised by the liver but is instead excreted unchanged in urine [13] . The evidence base includes three recent systematic reviews and meta-analyses [4, 6, 15] 
Pharmacokinetic Considerations and Implications for Safety
Acamprosate is derived from homotaurine, a non-specific GABA agonist, and calcium [13] . It is not metabolized by the liver and has no impact on drugs subject to hepatic metabolism or with an impact on the cytochrome P450 (CYP) system. It does not interact with alcohol, diazepam, oxazepam or imipramine [16] , and there is no evidence of an interaction with disulfiram [17] , although naltrexone increases its plasma levels in vivo [13] . It appears generally safe in patients with impaired hepatic function [13, 18] : in the RCTs reported here [19, 20] two deaths of patients receiving acamprosate were reported, one due to acute hepatic failure with pre-existing hepatic cirrhosis and one due to carcinoma, respectively. Given its predominately renal excretion, potential risks and benefits need to be considered on an individual basis in the elderly and in patients with renal insufficiency; the recommendation is to start at a lower dose (333 mg three times daily [tid] ) and monitor renal function [16] . A major concern when treating patients with addictions is the abuse liability of drugs prescribed. There is no evidence of abuse liability in clinical studies and none has been shown in animal models NICE CG115-review of evidence: 173
Cochrane Database SystemaƟc Reviews [6, 7] [21] . Acamprosate appears safe in overdose: reports from two studies of three patients taking intentional overdoses of 8-120 tablets indicated no 'untoward symptoms' [19, 22] . Acamprosate demonstrated a reasonable side effect profile in RCTs. Pharmacovigilance data [23] in 1.5 million patients indicated no serious adverse events, and a Cochrane review [6] found the most common side effects (significantly different from placebo) to be gastrointestinal symptoms (see Table 1 ), especially diarrhoea (effect size 0.11 [95 % CI 0.09-0.13]). If diarrhoea was severe, temporary dose reduction was beneficial [22, 24] . More recent studies not included in earlier meta-analyses [25, 26] confirm these earlier findings: diarrhoea was reported significantly more frequently in the acamprosate 1998 mg/day group (p = 0.004) and nervousness/anxiety was reported more frequently in the placebo group (p = 0.002) [26] .
Differences in how adverse events are collected has an impact on prevalence levels; where a 45-item checklist was used in addition to spontaneous reports [27] , the reported number of adverse events was higher but not significantly different between active medication (acamprosate 1998 mg/day) and placebo. In studies where acamprosate (1998 mg/day) was started before or during medically assisted withdrawal [28, 29] , no significant differences in adverse effects from placebo were reported.
Two studies [30, 31] examined the tolerability of low-(1.3 g/day) and high-dose (2.0 g/day) acamprosate compared with placebo. Neither found a significant difference in dropouts due to adverse effects between the groups. Diarrhoea was reported significantly more frequently with acamprosate and was dose dependent (3.3, 7.4, 12.1 %; p \ 0.01) in the placebo, low-and high-dose acamprosate groups, respectively, in one study [30] , and was frequent but not significantly different (39, 43, 48 %) between the respective groups in the other [31] .
The impact of combining acamprosate 1998 mg/day with naltrexone has been examined. One study [32] reported similar side effect profiles between groups, with the exception of diarrhoea and nausea, which showed significantly elevated scores in the combined group (naltrexone 50 mg/day). A similar analysis of the COMBINE study data [33] , using higher naltrexone doses (100 mg daily), showed significantly increased levels in the combined acamprosate and naltrexone group for nausea (42 %; p \ 0.001), vomiting (18 %; p \ 0.01), diarrhoea (56 %; p \ 0.001), decreased appetite (25 %; p \ 0.001), somnolence (31 %; p \ 0.05) and abnormal liver function tests (aspartate transaminase/alanine transaminase [AST/ALT] at five times the upper limit of normal: 2 %; p \ 0.05) when compared with placebo. Withdrawals due to adverse events were also greater (4 %) in the combined group (p \ 0.05).
Safety Considerations in Comorbid Conditions and Other Specific Patient Groups
One small double-blind RCT of acamprosate for alcohol dependence in patients with schizophrenia spectrum disorders found no effect of acamprosate 1998 mg/day on measures of memory, attention or executive function or on psychotic symptoms [34] . The study was underpowered, but the authors contend there were no specific safety concerns regarding acamprosate in this comorbid patient group. Another small double-blind RCT in patients with alcohol dependence and bipolar I or II disorder maintained on mood stabilisers found rates of all adverse events to be comparable between acamprosate 1998 mg/day and placebo: one patient in each group was withdrawn due to persistent suicidality, and one patient in the acamprosate group had an anaphylactic skin reaction on initiation of the drug. There were no completed suicides in either group [35] . These studies suggest acamprosate is safe and tolerable in patients with bipolar disorder and schizophrenia, but the numbers in both studies are small and probably insufficient to exclude uncommon adverse events. Adapted from Rosner et al. [6] A meta-analysis of the acamprosate trial database examined the prevalence of depression (measured with the Hamilton Depression Rating Scale [HDRS] ) and differences between patients with and without depression [36] . Different versions of the HDRS were used across studies, so scores were standardized using linear transformation and a cut-off of 17 to signify 'moderate' depression in the original HDRS-17 was standardized across scales to allow comparisons. Individual patient-level data from 3354 patients in the 11 studies that had values for the HDRS at baseline and follow-up were analysed. The prevalence of moderate/severe depression at baseline was 34.4 % (range : the effect of acamprosate on mood was mediated by percentage days' abstinence, and no specific safety concerns were identified in the co-morbidly depressed subgroup.
A recent multicentre double-blind RCT conducted in Japan [25] showed similar incidences in reported adverse events across the groups. Diarrhoea was significantly more frequent with acamprosate 1998 mg/day (12.9 vs. 4.9 %), but numerically more patients in the placebo group withdrew due to adverse events (6 vs. 1.8 %) during the administration period. A study in Chinese patients [37] found no differences in side effect profile between acamprosate (\60 kg, 1332 mg/day; C60 kg, 1998 mg/day) and placebo; the most common side effects were diarrhoea (4.9 vs. 3.2 %: v 2 = 0.36; p = 0.546) and erythema (3.9 vs. 2.1 %: v 2 = 0.53; p = 0.468), which all resolved without treatment. These studies suggest there are no obvious tolerability differences for acamprosate in Chinese or Japanese populations. A recent meta-analysis [38] concluded there were no sex differences in safety or tolerability for acamprosate.
Naltrexone

Oral Naltrexone
Oral preparations are licensed for relapse prevention in the UK, Australia, Asia, USA and much of Europe. Naltrexone is rapidly absorbed and reaches a peak plasma concentration within 1 h. It is subject to significant firstpass metabolism, creating the primary active metabolite 6-beta-naltrexol, which has a half-life of 13 h [39] , the levels of which correlate with adverse events [40] . A substantial evidence base includes systematic reviews and meta-analyses, which demonstrate a significant effect for naltrexone over placebo on relapse rates in heavy drinking (RR 0.83 [95 % CI 0.75-0.91]) [4] and on relapse to any drinking at 3 months (RR 0.92 [95 % CI 0.86-1.00]) [15] .
Pharmacokinetic Considerations and Implications for Safety
Evidence for a pharmacokinetic effect of naltrexone on other drugs is limited. The CYP enzyme system is not involved in metabolism of naltrexone or 6-beta-naltrexol, so interactions with drugs subject to hepatic metabolism are likely to be minimal [41] . Co-administration with acamprosate significantly increases acamprosate levels and side effects from acamprosate (see Sect. 3, above). Caution is advised for patients with liver dysfunction [4] and fiveto tenfold increases in naltrexone plasma concentrations have been reported in patients with cirrhosis [41] . Although not experimentally tested, evidence from RCTs suggests the interaction with alcohol is not dangerous, and naltrexone has not been found to produce physical or psychological dependence [39] . The most important reaction from a safety consideration is with other opioid drugs, and patients need to be advised against their concomitant use. Data suggest the concurrent use of non-steroidal analgesics with high-dose naltrexone may account for the raised transaminases seen in early studies [42] . A study of naltrexone 300 mg in obese patients [43] reported elevated hepatic enzyme levels. However, this was not repeated in patients with Huntington's disease [44] or eating disorders [45] or in patients with impulse-control disorders treated with naltrexone 200 mg daily for up to 1 year, with limited use of analgesics [46] . Phase II studies showed no evidence of toxicity at doses of 800 mg daily for 1 week [39] . A single RCT [47] reported a significant advantage for naltrexone 50 mg daily over placebo in lipid profile (with reduced total cholesterol and triglyceride concentrations) in recently abstinent patients. Data are limited on the impact of age on tolerability. In a single non-blinded RCT of naltrexone 100 mg/day and disulfiram 250-500 mg/day in Indian adolescents with alcohol dependence [48] , side effects were reported as 'uncommon': three patients experienced self-resolving 'neuritis' in the disulfiram group versus none in the naltrexone group (but no mention was made of how tolerability was assessed). A single study in patients aged [50 years [49] showed no significant differences between placebo and naltrexone 50 mg/day equivalent; sleep disturbance and anxiety were the most commonly reported effects.
Main Summary of Adverse Effects
A Cochrane review [7] of 47 studies analysed available data on side effects that were documented in each study and calculated the risk differences (RDs) for each of 46 different side effects listed in between 2 and 25 of the study reports. Table 2 shows the reported adverse events where there were significant risk ratios for naltrexone, and Table 3 summarises the side effects for which no difference was found between naltrexone and placebo. The most significant side effects attributable to naltrexone were nausea, vomiting, dizziness, abdominal pain, reduced appetite and day-time sleepiness.
The majority of studies used naltrexone 50 mg daily, though some [33, [50] [51] [52] [53] [54] investigated the tolerability of naltrexone 100 mg. Use of naltrexone 150 mg daily in patients with comorbid cocaine dependence [55] is discussed below, but a single open-label study by Yoon et al. [56] evaluated the safety of naltrexone 150 mg daily in patients with alcohol dependence (titrated up from 25 mg/day by week 3) over 8 weeks. All patients were given prochlorperazine 10 mg to reduce nausea in the first 3 days, and use of 'over-the-counter' analgesics was restricted, which may have affected the observation of raised transaminases in studies of higher-dose naltrexone in pathological gamblers [57] . Yoon et al. [56] report that the most common side effects (nausea, dizziness and drowsiness) occurred mainly in the early part of the study while patients were receiving the lower dose and that ''higher doses did not increase the frequency or severity of side effects''; hepatic transaminase profiles were stable.
RCTs assess safety considerations over a relatively small time frame, but a randomized single-blind trial of naltrexone 50 mg versus acamprosate (no placebo) over 1 year [58] found that symptoms resolved after the first 2 weeks of the study, with no long-term safety concerns.
Safety Considerations for Oral Naltrexone Combined with Other Medications
Polypharmacy increases safety concerns when prescribing a drug; however, given the only moderate effectiveness of licensed medications for the treatment of alcohol Adapted from Rosner et al. [7] CI confidence interval Adapted from Rosner et al. [7] dependence, the need to optimise outcomes has led to trials of combinations. The effect of acamprosate combined with naltrexone has been discussed above. A large study of naltrexone combined with disulfiram [59] was conducted in USA Veterans Administration (VA) outpatient clinics and included 254 patients with alcohol dependence comorbid with a major Axis I psychiatric disorder: patients were randomized (open label) to either disulfiram 250 mg or placebo and then underwent double-blind randomisation to naltrexone 50 mg/day or placebo. Participating patients were therefore in one of four treatment groups: combined naltrexone and disulfiram, disulfiram only, naltrexone only, or placebo only. In the full sample, those in the combined group were significantly more likely to report abdominal pain, nausea, vomiting, numb limbs, pins and needles, irregular heart beat and restlessness (all p B 0.05) than either monotherapy medication. Differences were observed in side effect profiles within subsamples; these are discussed in the comorbidity section below. Two small studies examined the combination of ondansetron (a 5-HT 3 antagonist) with naltrexone. Johnson et al. [60] added either naltrexone 50 mg/day or placebo to ondansetron for 8 weeks and reported no significant side effects. Myrick et al. [61] conducted a four-arm doubleblind functional magnetic resonance imaging (fMRI) study with naltrexone, ondansetron and placebo in combination for 7 days. The main side effects (nausea/vomiting and dizziness) were significantly more likely in the naltrexone group, with no difference in side effects between the ondansetron or placebo groups.
Gabapentin (titrated to 1200 mg/day) added to naltrexone 50 mg/day for the first 6 weeks of a 16-week treatment programme was compared with double placebo, after 4 days' abstinence. The combination group reported more daytime somnolence (p = 0.02), blurred vision (p = 0.02) and premature ejaculation (p = 0.02) but more improved sleep quality than the other groups, and the combination was well tolerated overall.
A 3-month open-label randomized three-arm comparative study of c-hydroxybutyric acid (GHB) and naltrexone 50 mg/day [62] , as monotherapy and in combination (no placebo arm), reported a significantly higher side effect burden in the combination group than in the GHB group, specifically, vertigo (5/18 vs. 2/20) and nausea (4/18 vs. 0/20). Five patients discontinued due to side effects, three in the combination group and one in each of the other arms. The numbers are too small to be interpreted reliably, but tolerability and safety in this combination require further study. Another Italian study [63] of uncertain design described 47 patients treated in four groups: escitalopram 20 mg/day only; naltrexone 50 mg/day ? escitalopram 20 mg/day; GHB 75 mg/kg ? escitalopram 20 mg/day; naltrexone 50 mg/day ? GHB 75 mg/kg ? escitalopram 20 mg/day. Hyperalgesia was significantly more common in the naltrexone-treated groups when compared with the other groups. These findings need to be replicated in a larger sample with a placebo arm.
Two studies examined the effect of naltrexone combined with sertraline in alcohol-dependent patients without comorbid depression. A double-blind RCT [64] of naltrexone 50 mg/day and sertraline (titrated to 100 mg/day) found significantly increased rates of nausea, sleepiness and dizziness in the combined group. Farren et al. [65] conducted a similar study (naltrexone 100 mg/day) and reported similar levels of common side effects between groups, with the exception of sexual dysfunction, which was significantly more common in the combination group (68 vs. 24 %, p \ 0.001). Finally, a double-blind study adding quetiapine 25-200 mg daily or placebo to naltrexone 50 mg/day showed no additional benefit or side-effect burden beyond that of naltrexone [66] .
Safety Considerations for Oral Naltrexone in Patients with Comorbid Psychiatric Conditions
Literature is emerging on the role of naltrexone in alcoholdependent patients with comorbid Axis 1 psychiatric disorders. Naltrexone is not licenced for use in patients with comorbid psychopathology, but given the high prevalence, they constitute an important area for safety considerations in clinical practice. Some data (of varying quality) are available for patients with alcohol dependence and comorbid cocaine dependence, depression, bipolar disorder, post-traumatic stress disorder (PTSD), psychotic disorders and eating disorders.
Cocaine and Alcohol Dependence (CAD) Five
RCTs investigated the safety and efficacy of naltrexone in the treatment of comorbid cocaine and alcohol dependence (CAD) in relapse prevention [53, 55, 67] or abstinence initiation [54, 68] . None found any significant benefit for active medication (50 mg/day [67, 68] Pettinati et al. [53] also investigated naltrexone 100 mg/day, disulfiram 250 mg/day, both separately and combined, versus placebo in patients with CAD. There were no serious medical complications or deaths during the study: headache, drowsiness, anxiety/irritability and nausea were the most commonly reported adverse events, but only nausea was significantly more frequent in the active medication groups (p = 0.01). Increased sexual desire was more common in the combination medication group (33 %) but not significantly more frequent than with placebo (28 %).
Depression and Alcohol Dependence
The prevalence of depression co-occurrence has been found to range from 24 to 48 % in alcohol-dependent men and women, respectively, and to range from 50 to 70 % in clinical samples [70] , but this substantially reduces following detoxification and abstinence [71] . Although the recommendation [4, 8] is to wait until the patient is 3-4 weeks abstinent from alcohol to reassess mood and need for treatment, both conditions often need to be addressed concurrently. Four RCTs investigated naltrexone in this patient group. Oslin [72] examined older patients (aged C 55 years), post detoxification, who started naltrexone 50 mg/day or placebo. After 1 week, all patients still met criteria for depression, and sertraline 50 mg/day was added and increased to 100 mg/day after 1 week if tolerated, for 12 weeks. Adverse events were screened using a checklist and, although reporting of headache, anxiety, nausea, vomiting and decreased sexual function was common, none were more common with naltrexone ? sertraline than with placebo ? sertraline. Pettinati et al. [50] conducted a fourarm RCT of sertraline 200 mg/day, naltrexone 100 mg/day, sertraline 200 mg/day ? naltrexone 100 mg/day, and placebo. The most frequent serious adverse event was a requirement for inpatient detoxification, which correlated with a poor outcome rather than tolerability and was significantly less frequent with naltrexone ? sertraline than in the other groups combined. There were no differences between groups in reports of symptoms of irritability, fatigue, decreased sexual desire, headache or nausea, but 7 of 42 (*17 %) patients in the naltrexone ? sertraline group compared with only 1 of 40 (2.5 %) in the placebo group withdrew due to adverse effects.
Adamson et al. [73] reported a 12-week parallel-group trial in alcohol-dependent patients with comorbid depression: 138 patients were randomized to citalopram 20 mg/day or placebo, increasing after 1 week if required, and all patients were then also prescribed naltrexone 50 mg/day. Patients were not required to be abstinent at baseline. Overall, 90.4 % of the citalopram ? naltrexone group and 87.7 % of the placebo ? naltrexone group reported one or more adverse events, with 'severe' events more likely in the citalopram group (p = 0.049). The most common adverse events were difficulty sleeping, nausea and low energy, although the latter was the only event that occurred more frequently with citalopram: two patients were withdrawn (one with suicidal ideation and one with severe abdominal cramps), both in the citalopram ? naltrexone group.
Petrakis et al. [74] reported a subgroup of 139 patients with alcohol dependence and depression in the four-arm naltrexone 50 mg/day ? disulfiram 250 mg/day study conducted in US VA outpatient clinics described above. There was no difference in adverse events between the groups, and the authors concluded that disulfiram and naltrexone were safe, both singly and in combination in this comorbid patient group.
Depression and Bipolar Disorder and Psychoses
Two studies examined the use of naltrexone 50 mg/day in patients with bipolar disorder [75, 76] . Petrakis et al. [76] reported a sub-analysis of 66 patients with 'psychotic spectrum disorder', 73 % of whom had bipolar disorder (the remaining participants had schizophrenia or schizoaffective disorder). As expected, patients with psychotic spectrum disorders were significantly more likely to be prescribed atypical and/or typical antipsychotics (15 and 28.7 %, respectively), lithium (15 %) or anticonvulsant medications (35 %) than those in the 'non-psychotic' group. This may have an impact on tolerability, with patients with psychotic spectrum disorders significantly more likely to report abdominal pain, sweating and tremors than those in the non-psychotic spectrum group, whether they were receiving active treatment or placebo. A small double-blind RCT in patients with bipolar disorder [75] added naltrexone or placebo to continued usual medication (lithium, anticonvulsants, antipsychotics and/or antidepressants). There was no interaction with valproate, and the change in side-effect burden was not significantly different between adjuvant naltrexone and placebo. A small RCT of naltrexone 50 mg/day augmentation of 'treatment as usual' in patients with schizophrenia [77] concluded that naltrexone had no effect on psychotic symptoms and was well tolerated.
Comorbid Conditions and Other Specific Patient
Groups In a further sub-analysis of the VA group, Petrakis et al. [78] reported on 93 patients with PTSD (91 male): patients were more likely to report gastrointestinal (p = 0.05), emotional, cold/flu and neurological symptoms than those without PTSD (all p \ 0.02). Patients receiving combined disulfiram 250 mg/day and naltrexone 50 mg/day in the PTSD group were significantly more likely to report cardiac or sexual side effects and had higher post-traumatic re-experiencing symptoms than those receiving either medication alone. One patient in the combined disulfiram/naltrexone group experienced an alcohol/disulfiram reaction. In a separate study [79] , 88 patients were randomized to one of four groups (paroxetine 40 mg/day or desipramine 200 mg/day, with naltrexone 50 mg/day or placebo), but there was no significant difference in side-effect reporting between groups. Several studies have included patients with co-morbid alcohol dependence psychiatric disorders [80] [81] [82] . None of these show significantly different side-effect profiles from those in non-comorbid groups.
There is some evidence that naltrexone tolerability is worse in women. The observation of higher levels of nausea in women with CAD was discussed above. O'Malley et al. [83] reported a study of naltrexone 50 mg/day in 103 women (29 with comorbid eating disorders): no differences in adverse events across the medication or diagnostic group were found, but significantly more who reported any event were in the naltrexone group, and the most common significant individual events were decreased appetite, depression and dizziness. In an earlier open-labeltrial (naltrexone 50 mg/day) [84] , a regression analysis of 120 patients found younger age, female sex and less severe alcohol use were associated with increased nausea. Baros et al. [85] reported on pooled data from two earlier studies [86, 87] and found that women experienced more nausea while receiving naltrexone 50 mg/day compared with placebo (38 vs. 8 %; p = 0.01), though this had no impact on outcome, and concluded that reported sex differences may reflect study design rather than inherent pharmacological or biological differences in response. The naltrexone 50 mg/day studies have been conducted in a wide range of ethnic groups, including Iranian [88] , Taiwan Han [89] , Indian and Chinese ethnic males in Singapore [90] , American Indians and Alaskan Natives [64] , Black African Americans, Hispanic Americans, Northern and Southern Europeans, and Australians, with no significant difference between groups in the observed safety profile.
The Extended-Release Injectable Suspension of Naltrexone
The extended-release injectable suspension of naltrexone is currently only licensed in the USA, Russia, Ukraine, Azerbaijan, Kazakhstan and Belarus. Its primary purpose is to improve compliance, as studies of oral naltrexone 50 mg/day show it to be superior to placebo only when compliance is [80 % [91] or [90 % [92] . As the injectable suspension has reduced plasma levels and lower first-pass metabolism, it is anticipated that levels of the metabolite 6-beta-naltrexol would be reduced, potentially reducing adverse effects [93] .
Pharmacokinetic Considerations and Implications for Safety
The main pharmacokinetic differences between long-acting injectable naltrexone and the oral preparation are the lack of daily naltrexone peaks and the reduced ratio of 6-beta-naltrexol. In a preliminary double-blind RCT [94] , 20 alcohol-dependent patients were administered either subcutaneous naltrexone 206 mg (N = 15) or placebo injection (N = 5) after 2 weeks of oral naltrexone, followed by a 2-week washout period. The main side effects were pain and induration at the injection site in both groups; all other adverse events were comparable in frequency to those during the oral naltrexone period. A small double-blind RCT [93] involving 30 participants (25 received intramuscular naltrexone 400 mg monthly, five received intramuscular placebo monthly) found adverse event reporting to be similar to that with oral naltrexone, with the addition of injection site pain in 4 of 25 of the injectable naltrexone group but in none with placebo injection. Two patients (8 %) withdrew after the second naltrexone injection due to site injection induration and angioedema. As predicted, plasma concentrations of 6-beta-naltrexol were lower than after oral administration, but this did not appear to reduce the side-effect burden. Kranzler et al. [95] randomized 215 patients to intramuscular naltrexone 300 mg followed by intramuscular naltrexone 150 mg monthly or placebo for 3 months: 4 % of patients in both groups withdrew due to injection site reactions. The most common adverse events were headache, nausea and fatigue; upper abdominal pain was more common with the naltrexone group and irritability and chest pain were more common with placebo. There was a trend for pain to be more common at the naltrexone injection site. Garbutt et al. [96] conducted a three-arm RCT of intramuscular naltrexone 380 mg, 190 mg or matching placebo: withdrawal due to adverse events occurred in 14.1 % in the 380-mg group, 6.7 % in the 190-mg group and 6.7 % in the placebo group, due to dose-dependent rates of nausea, injection site reaction and headache. There were significant dose-dependent differences in reports of decreased appetite and dizziness. Two cases of pneumonia in the naltrexone 380-mg group were judged to be possibly related to medication. No effect of medication dose was found on increased levels of transaminases.
Disulfiram
Disulfiram acts via irreversible inactivation of liver acetaldehyde dehydrogenase (ALDH) enzymes. ALDHs catalyse the conversion of acetaldehyde into acetic acid during the metabolism of alcohol. Inactivation therefore results in an increased concentration of intracellular acetaldehyde when alcohol is taken. Disulfiram also inhibits the conversion of dopamine to noradrenaline, and the depletion of noradrenaline in the cardiovascular system allows acetaldehyde to act directly on myocardial and vascular tissue to cause flushing, tachycardia and hypotension. Other symptoms of the disulfiram-alcohol reaction (DAR) include hyperthermia, headache, chest pain and respiratory depression or hyperventilation, which may be mild or life threatening. Intra-individual variation in the severity of the DAR is substantial because of variations in which polymorphisms are expressed or mutations are present in different parts of the alcohol oxidative pathway and because of the complex metabolic pathway of disulfiram [97] , which makes it hard to predict the response in any individual.
Pharmacokinetic Considerations and Implications for Safety
Disulfiram is converted by gastric acid to diethyldithiocarbamate, which is a strong metal-chelating agent [98] and may account for the mild but unpleasant side effect of 'metallic taste' [99] . Disulfiram is metabolized in the liver and inhibits the metabolism of drugs such as phenytoin and warfarin which use the CYP450 and CYP2E1 systems, leading to increased levels [100] . It also inhibits the metabolism of chlordiazepoxide and diazepam (but not oxazepam), increasing their sedative effects [98, 101] . Rothstein and Clancy [102] reported an RCT of 58 inpatients prescribed disulfiram 500 mg/day for 30 days then 250 mg/day then randomized to adjuvant metronidazole 750 mg or placebo: 6 of 29 of those receiving coprescribed metronidazole developed a 'confusional psychosis', reversible on discontinuation, with no benefit for the addition of metronidazole.
Undertaking an alcohol challenge in patients receiving disulfiram is not recommended in clinical practice. Rather, patients and carers should be given clear instructions about potential hazards and sources of alcohol in consumables. In a controlled setting of 60 alcohol-dependent patients prescribed disulfiram 250 mg/day, Kumaraswamy et al. [103] gave each an alcohol challenge: symptoms of the DAR started within 10-15 min and lasted between 90 and 240 min. Tachycardia, hypotension and transient ischaemic changes on electrocardiogram (ECG) were most commonly noted, although 38 % showed no significant ECG changes; all recovered, but those with hypotension required intravenous fluid stabilisation.
Overdose with disulfiram as a sole agent has relatively low toxicity, but given the irreversible effect on ALDH, patients require observation until ALDH is active again. No abuse liability has been shown for disulfiram.
Main Summary of Adverse Effects
The evidence base for disulfiram is less robust than for other medications licensed for the treatment of AUD, primarily because of difficulties (both ethical and pragmatic) in subjecting it to a double-blind RCT (see the Table 1 in the Electronic Supplementary Material [ESM] ). However, four RCTs conducted in alcohol-dependent populations [104] [105] [106] [107] (disulfiram 200 mg/day [102] , 250 mg/day [103, 104] or 800 mg twice per week [105] ) all found it was generally well tolerated over 6-12 months and did not cause any hepatitis. Drowsiness was the only reported adverse event found significantly more frequently in patients receiving disulfiram 250 mg compared with 1 mg (active control) or placebo [105] ; altered liver function (elevated AST and bilirubin) was not related to disulfiram treatment, but was significantly related to drinking status [106] . Similarly, Chick et al. [104] found mean serum cglutamyl transferase [GGT] dropped by 21 IU/l in patients receiving disulfiram but increased by a mean of 13 IU/l in those receiving a placebo vitamin C tablet. Headache, fatigue, skin rashes and an unpleasant aftertaste occurred more commonly with disulfiram than with placebo and improved with dose reduction when that was undertaken [104, 107] . DARs were reported on 29 occasions [104] , but none led to a dose reduction, and the authors concluded that disulfiram was well tolerated when administered as part of a wider treatment programme. A small cohort study of more than 50 weeks' duration (disulfiram 1.5 g/week) [108] did not raise any long-term safety concerns. A more recent 2-month prospective cohort study in an Indian population (125 mg/day) [109] showed an excess of skin rashes, supporting an earlier observation that there may be greater sensitivity to the adverse effects of disulfiram in Indian than in Western patients [110] . A study in adolescents [111] found it to be well tolerated, with no significant differences in reported adverse events between disulfiram 200 mg/day and placebo.
Early studies of disulfiram used much higher doses (1-3 g/day), causing a higher burden of serious adverse effects and DARs, including death [110] . In one variabledose study, disulfiram 500 mg was much less tolerated than 250 mg, with all withdrawals due to adverse events in the 500 mg group [112] .
Safety Considerations for Disulfiram Combined with Other Medications
Disulfiram has also been investigated in a number of studies of alcohol dependence with comorbid opioid substitution therapy (OST). An early study that was stopped after 12 weeks because of the small sample size [113] reported safety data in 35/82 study completers: all patients had been stable while receiving methadone for at least 3 months before being randomized to disulfiram 250 mg or placebo. No serious adverse events attributable to the combination of methadone and disulfiram were reported. In a recent prospective cohort study of 29 patients receiving OST at variable doses [114] , in which participants received disulfiram 100-300 mg/day for 6 months, 50 % completed the study and three patients (10 %) reported serious adverse reactions attributable to disulfiram, although there was no control group (see Table 1 in the ESM).
Safety Considerations for Disulfiram in Patients with Comorbid Psychiatric Conditions
Two placebo-controlled studies have assessed the effects of disulfiram 250-500 mg/day in patients with CAD [53, 115] : the latter was discussed in the naltrexone section (above). Combining disulfiram with careful monitoring was considered safe with few serious adverse events. Laboratory studies of the disulfiram-cocaine-alcohol interaction in volunteers found that disulfiram increased cocaine levels and duration, with mild elevations of blood pressure and heart rate that were not clinically significant [116] . The main evidence for using disulfiram in patients with alcohol dependence and comorbid Axis 1 disorders comes from the VA study reported by Petrakis and colleagues [59, 74, 76, 78 ] described above: none identified any specific concerns regarding the use of disulfiram in patients with psychotic spectrum disorders, PTSD or depression (see Table 1 in the ESM). Earlier concerns about the potential for disulfiram to cause psychosis in vulnerable groups were based on doses of 1-3 g/day [117] and have not been reported recently [8] .
Nalmefene
Nalmefene is an opioid system modulator that is structurally similar to naltrexone; however, it has a methylene group at the sixth carbon, where naltrexone has a ketone group. It has a slightly different receptor profile, acting as a mu receptor antagonist and kappa receptor partial agonist [118] , but, like naltrexone, has no opioid mu agonist activity or abuse potential [119] . It is licenced in Europe for the reduction of alcohol consumption in patients not requiring medically assisted withdrawal.
Pharmacokinetic Considerations and Implications for Safety
Nalmefene was originally developed to reverse the effects of opioid overdose and anaesthesia [118] , and the benefits of opioid analgesics may not be felt if taken concomitantly with nalmefene. As with naltrexone, there are no clinical safety concerns around co-ingestion with alcohol, and in vitro studies have indicated it has no relevant interactions with other drugs metabolised by the CYP450 and uridine 5 0 -diphospho-glucuronosyltransferase (UDP)-glucuronosyltransferase (UGT) systems. Chronic use of potent inhibitors of the UGT2B7 system (e.g. diclofenac) may increase nalmefene levels, but occasional use does not [120] .
Nalmefene is extensively metabolized in the liver, largely by glucuronidation rather than transformation to a different metabolite. Unlike naltrexone, there is no identified risk of hepatotoxicity [121] , but clearance of nalmefene was found to be significantly reduced in a small study of patients with liver disease, and was inversely proportional to the level of hepatic pathology [122] .
A Cochrane review [7] included a meta-analysis of the two earlier studies on nalmefene conducted in the USA. The authors found that two adverse events were reported significantly more frequently by patients receiving nalmefene than by those receiving placebo: insomnia (effect size 0.12 [ Drobes et al. [124] described an 8-day trial to assess the impact of nalmefene 40 mg/day, naltrexone 50 mg/day or placebo in 125 alcohol-dependent people. Patients in the nalmefene group reported significantly higher levels of poor sleep, irritability, trouble concentrating, decreased libido and headache than those in either the naltrexone or the placebo group. Patients prescribed naltrexone reported significantly more nausea/vomiting over the 6 days of medication.
Two large multicentre double-blind placebo-controlled 3-month trials of nalmefene [125, 126] and one 12-month safety trial [127] have been conducted in alcohol-dependent patients not in need of medically assisted detoxification, but who wished to reduce or stop their alcohol consumption. Medication was taken on an 'as needed' basis, up to once daily. In the first study [126] , patients were randomized to nalmefene 18 mg/day or placebo. Treatment-emergent adverse events were given as the reason for withdrawal in 91 patients: 69 (23 %) in the nalmefene group (primarily dizziness, nausea, fatigue and headache), and 22 (7 %) in the placebo group. Other common side effects (sleep disorder, insomnia, vomiting and hyperhidrosis) were twice as likely with nalmefene as with placebo, but most were of mild or moderate intensity and occurred within 1 day of the first dose. Two patients committed suicide, both in the placebo group. In the second study [125] , in which 341 patients were randomized to nalmefene 18 mg/day and 337 to placebo, 68 and 59 % of patients, respectively, experienced treatment-emergent adverse events. Nausea, dizziness and insomnia occurred twice as often with nalmefene as with placebo. Withdrawal due to adverse events occurred in 5.9 % of the placebo and 6.7 % of the nalmefene group; 14 patients (four placebo, ten nalmefene) experienced a psychiatric adverse event, but none was described as serious, and all settled. Two patients died: one in the nalmefene group (cause unknown) and one in the placebo group (secondary to hepatocellular carcinoma).
In the 52-week safety study [127] , 501 patients were randomized to nalmefene 18 mg/day and 164 were randomized to placebo. A similar pattern of treatment-emergent adverse events was reported (nausea, insomnia, dizziness, vomiting and fatigue were reported twice as frequently as with placebo). The vast majority of adverse events (97 %) were mild or moderate in intensity and occurred at the beginning of the study. Serious adverse events were reported in 5.4 % of the placebo and 6.4 % of the nalmefene group: the majority were not considered by investigators to be related to the study medication. In total, 18 patients (1 % receiving placebo and 3 % receiving nalmefene) reported a psychiatric adverse event, two patients (both receiving nalmefene) experienced disorientation (one severe and one moderate). There were no differences between treatment groups, or changes over time for weight, ECG parameters or vital signs. At month 13, GGT and alanine aminotransferase (ALAT) values remained higher in the placebo group.
Finally, a sub-analysis of all patients at high or very high levels of drinking risk combined from the three studies above [128] did not find any specific differences from the full population.
Baclofen
Baclofen is a GABA-B agonist that has been used in the treatment of spasticity for many years. It currently has a 'temporary recommendation for use' in France for the maintenance of alcohol abstinence or for the reduction of consumption to low levels in patients with alcohol dependence who have not responded to other treatments [129] .
Some studies have demonstrated the effectiveness of baclofen in alcohol-dependent patients [130] [131] [132] but they are small, and further trials are underway; current data inform the safety considerations presented here.
Pharmacokinetic Considerations and Implications for Safety
The precise mechanism of baclofen is not fully understood. It is rapidly absorbed, and excreted primarily by the kidney unchanged, but there appears to be significant inter-subject variation in absorption and elimination. Although extensively used in patients with spasticity, safety considerations in patients with AUD may well differ. The lack of hepatic metabolism makes it potentially useful in patients with comorbid liver disease [133, 134] . Use in patients with renal disease, or in the elderly, who may have reduced renal capacity, has not been systematically studied. A case series reported on four alcohol-dependent patients in India who developed morbilliform rashes on initiation of treatment; these were dose dependent and resolved with drug cessation [135] . An early open-label RCT in Russia [136] that compared baclofen 37.5 mg/day with amitriptyline 75 mg/day or diazepam 15 mg/day in 'alcoholic patients with secondary affective disorders' who had been abstinent for 3-4 weeks found it to have ''no side effects'', but how this was assessed is not clear. There have now been seven subsequent double-blind RCTs [130] [131] [132] [137] [138] [139] [140] (see Table 2 in the ESM). Not all have demonstrated efficacy over placebo, but, overall, baclofen 30 mg/day appears well tolerated, and no specific safety concerns have been raised, including in patients with liver cirrhosis [131] or hepatitis C [134] . Indices of liver failure (alpha-1 antitrypsin [AAT], bilirubin, international normalized ratio [INR] and GGT) significantly improved in the baclofen group (due to reduced drinking), and there were no instances of encephalopathy or craving for or liking of baclofen, and no evidence for a discontinuation syndrome [129, 130, 140] . More recent studies (baclofen doses ranged from 30 to 270 mg/day) [132, [137] [138] [139] found that headache and drowsiness were most commonly reported, although not significantly more frequently with baclofen than with placebo.
Several studies have examined the impact of higher doses of baclofen. The first was a 2-year observational study of 100 patients [141] in which the mean maximal dose of baclofen was 147 mg/day (range 20-330 mg). A wide range of side effects of mostly mild intensity were reported by 88 % of patients, with no relationship between side effects and treatment response. In another prospective cohort study [142] involving 253 patients treated for up to 1 year, episodes of major sedation were recorded and the relationship between them investigated using a generalised estimating equation (GEE) model. The rate of sedation episodes increased with levels of alcohol and baclofen daily dose separately and showed a significant interaction between the two. The first reported double-blind RCT [132] of 56 patients individually titrated to daily doses of baclofen between 30 and 270 mg reported that doses were well tolerated with no drug-related serious adverse effects, and no discontinuation symptoms, including craving. A small and retrospective case series suggested the existence of a 'baclofen withdrawal syndrome' [143] , but this requires more robust prospective investigation. The same group also reported a nested cohort study of 23 alcoholdependent patients treated with high-dose baclofen (mean dose 124.5 ± 67.2 mg/day) who also had borderline personality disorder [144] : those with comorbid personality disorder reported a significantly higher number of adverse events (65.2 vs. 6.5 %; p \ 0.001) and rates of treatment discontinuation after adverse events (52.2 vs. 8.6 %; p \ 0.001).
The main safety considerations relate to co-administration with other central nervous system (CNS) depressants (e.g. opioids, benzodiazepines, tricyclic antidepressants) and anti-hypertensives. The increase in prescriptions for baclofen for AUD has resulted in its use in more episodes of selfpoisoning. The clinical presentation of baclofen overdose is related to its inhibitory neurotransmitter effects and includes coma, hypotonia, respiratory depression, seizures and cardiac abnormalities, and-at higher doses-autonomic effects such as hypertension and CNS depression [145] . In a consecutive series of 23 self-poisoning presentations to a regional toxicology service in Australia [146] , in which baclofen doses consumed ranged between 80 and 2500 mg, seizures were reported in four cases (three with baclofen only), 16 patients required admission to the intensive care unit (ICU), and 11 required intubation (median 32 h). Baclofen doses \200 mg were not associated with severe effects, but delirium, seizures and coma occurred at higher doses, including six of the seven patients who co-ingested alcohol. A recent report compared 14 consecutive emergency presentations in alcohol-dependent patients treated with baclofen following intentional poisoning to 56 matched patients presenting with overdose from another neuro-depressant medicine [147] . Alcohol co-ingestion occurred in 78.6 % of baclofen-poisoned patients compared with 48.2 % in the control group (p = 0.07): they were significantly more likely to be admitted to an intensive therapy unit (ITU), and to require mechanical ventilation. A retrospective review of 12 patients admitted following baclofen overdose (ranging between 140 and 800 mg; median 340 mg) [145] noted that ten patients had made previous suicide attempts, that benzodiazepines and alcohol were frequently coingested and that there was a dose-dependent relationship in the severity of medical symptoms.
Discussion
Summary of Main Findings
Acamprosate appears safe and well-tolerated for the maintenance of abstinence in alcohol-dependent patients, with no significant safety concerns across a wide range of patient groups, including those with major mental illness. It is safe in overdose and when taken with alcohol. Its main side effect is diarrhoea that settles within a few days or with dose reduction if severe. Acamprosate plasma levels and side effects are increased by naltrexone and potentially in the elderly and those with significant renal insufficiency. It is recommended as a first-line treatment for the maintenance of abstinence [4, 148] .
Early concerns about oral naltrexone causing hepatotoxicity have not been replicated in patients with alcohol dependence, although monitoring is still advised [4] and the use of non-steroidal analgesics should be limited. It has a moderate side effect burden, specifically gastrointestinal symptoms, headache and drowsiness/fatigue, which are dose dependent and appear to be worse in women. There are no significant safety concerns regarding the use of naltrexone in patients with alcohol dependence comorbid with depression. However, some evidence exists that combining it with sertraline makes naltrexone less tolerable at higher doses (naltrexone 100 mg, sertraline 200 mg) even though this may be more effective. Combinations with acamprosate, disulfiram, ondansetron, gabapentin, olanzapine and sertraline were all safe although the sideeffect burden increased. However, the risk-benefit ratio for combining naltrexone with citalopram or GHB is less certain and requires further investigation. Taken together, the hypothesized benefits on tolerability from the injectable formula do not seem to have been realised; in addition, substantial adverse events at the injection site have been experienced. The potential benefit of injectable naltrexone over the oral preparation appears to be related to improved adherence rather than improved tolerability, and other safety considerations remain untested.
The safety profile of nalmefene is similar overall to that of naltrexone, but its action as a partial agonist at the opioid kappa receptor may account for the increased reporting of CNS symptoms (dizziness, insomnia, disorientation). There are no significant concerns regarding use in patients with liver pathology, and the clinical trials specifically tested its co-ingestion with alcohol and found this to be safe. Several reviews of the safety of disulfiram [98, 104, 149] have concluded that the moderately severe side-effect profile for disulfiram \250 mg daily can be mitigated by careful patient selection and supervision for those patients (including those with co-morbid cocaine addiction) in whom it may be effective. The DAR remains potentially serious if both disulfiram and alcohol are taken at high doses.
There are substantial safety considerations regarding self-poisoning with baclofen, particularly in conjunction with alcohol, as both are CNS depressants. If taken at high levels, timely medical intervention is needed to prevent respiratory depression. Concomitant prescribing with other CNS depressants requires a careful risk-benefit assessment, and evidence to date suggests it is safer to use it to maintain rather than initiate abstinence in those with no suicidal tendencies. It may have a particular role in the treatment of alcohol-related liver disease. Optimal therapeutic doses, along with the relative safety risks of higher doses, have yet to be established.
In addition to the medications reviewed here, other medicines are being investigated in patients with alcohol dependence, including ondansetron (discussed above) and topiramate. The first trial (using topiramate 300 mg/day) found it to have significant side effects (including paraesthesia, nausea, cognitive impairment and headache),which were reduced when a lower dose (200 mg/day) and slower titration were used [150, 151] .
Areas of Uncertainty
The use of clinical trial data to examine safety and tolerability has the advantage of comparison with placebo and more systematic recording of adverse events. This is particularly necessary in patients with alcohol dependence who have high placebo responses to treatment and a high incidence of adverse events [128, 152, 153] . However, RCTs typically exclude patients with significant physical or psychiatric comorbidity [98] , which obscures potential safety concerns in the wider group of patients seen in clinical practice. In patients with alcohol dependence especially, any medication to initiate abstinence or reduce drinking needs to have good evidence for the safety of the drug combined with alcohol, which seems well established for nalmefene [128] but less clear for baclofen [142] . For medications that aim to promote abstinence from alcohol, the safety profile needs to be weighed against the risks to the patient of relapse [110] , but the prescriber also needs to consider potential interactions with concomitantly prescribed medications in a patient group with considerable physical and psychiatric comorbidity. Baclofen is a good example of how the 'repurposing' of drugs in a different patient group may alter the safety profile, as was also seen in early reports of hepatotoxicity of naltrexone in non-alcohol-dependent obese patients. Improved and more consistent reporting of case reports and case series may help identify significant safety concerns [12, 154] that do not come to light in clinical trials.
Conclusions
Alcohol dependence is responsible for a substantial burden of disease. Pharmacotherapy is underused in its treatment despite evidence of moderate effect [152] , similar to that in other conditions [155] . Acamprosate, naltrexone and nalmefene have a substantial evidence base for being generally well-tolerated, and disulfiram risks are well known and can be mitigated with appropriate patient selection and supervision. There are some positive initial reports regarding baclofen in patients with alcohol dependence, but its safety profile, including its therapeutic dose range, interaction with other CNS depressants and abuse liability, have yet to be established.
